The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2022

Filed:

Jun. 21, 2019
Applicants:

Massachusetts Institute of Technology, Cambridge, MA (US);

The Broad Institute, Inc., Cambridge, MA (US);

Inventors:

Chengcheng Jin, Cambridge, MA (US);

Georgia Lagoudas, Cambridge, MA (US);

Paul Blainey, Cambridge, MA (US);

Tyler Jacks, Newton, MA (US);

Assignees:

Massachusetts Institute of Technology, Cambridge, MA (US);

The Broad Institute, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/00 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 31/43 (2006.01); A61K 31/7036 (2006.01); A61K 31/4164 (2006.01); A61K 38/08 (2019.01); A61K 31/7052 (2006.01); A61K 31/7048 (2006.01); A61K 31/7056 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0073 (2013.01); A61K 31/4164 (2013.01); A61K 31/43 (2013.01); A61K 31/7036 (2013.01); A61K 31/7048 (2013.01); A61K 31/7052 (2013.01); A61K 31/7056 (2013.01); A61K 38/08 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/244 (2013.01); C07K 16/245 (2013.01); C07K 16/2866 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01);
Abstract

It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.


Find Patent Forward Citations

Loading…